Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Judson

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyJ Verweij, A van Oosterom, J-Y Blay, et al.
British Journal of Cancer|February 20, 2003
Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profilingY-F Lee, M John, S Edwards, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupO S Nielsen, I Judson, Q van Hoesel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialA Le Cesne, J Y Blay, I Judson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2001
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma GroupI Judson, J A Radford, M Harris, et al.
British Journal of Cancer|November 26, 2009
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopyC P Lee, G S Payne, A Oregioni, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 28, 2019
Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma CentreC Drabbe, C Benson, E Younger, et al.
British Journal of Cancer|May 30, 2018
Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter studyA Y Zhang, I Judson, C Benson, et al.
British Journal of Cancer|June 28, 2017
Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter studyA Y Zhang, I Judson, C Benson, et al.
Gynecologic Oncology|March 26, 2016
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072C Benson, I Ray-Coquard, S Sleijfer, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyJ Verweij, A van Oosterom, J-Y Blay, et al.
British Journal of Cancer|February 20, 2003
Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profilingY-F Lee, M John, S Edwards, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupO S Nielsen, I Judson, Q van Hoesel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialA Le Cesne, J Y Blay, I Judson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2001
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma GroupI Judson, J A Radford, M Harris, et al.
British Journal of Cancer|November 26, 2009
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopyC P Lee, G S Payne, A Oregioni, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 28, 2019
Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma CentreC Drabbe, C Benson, E Younger, et al.
British Journal of Cancer|May 30, 2018
Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter studyA Y Zhang, I Judson, C Benson, et al.
British Journal of Cancer|June 28, 2017
Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter studyA Y Zhang, I Judson, C Benson, et al.
Gynecologic Oncology|March 26, 2016
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072C Benson, I Ray-Coquard, S Sleijfer, et al.
Pageof 12